Literature DB >> 15956274

Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia.

Marci L Chew1, Benoit H Mulsant, Bruce G Pollock.   

Abstract

OBJECTIVE: The authors investigated the association between serum anticholinergic activity (SAA) and cognitive performance in a group of patients with moderate-to-severe dementia.
METHODS: SAA and cognitive performance were assessed in 26 patients admitted to a geropsychiatric unit for the treatment of behavioral disturbances associated with dementia. SAA was measured by radioreceptor competitive binding assay. Cognition was tested with the Mini-Mental State Exam and the Severe Impairment Battery.
RESULTS: Higher SAA was associated with lower cognitive performance.
CONCLUSION: This study extends to patients with moderate-to-severe dementia the finding that higher SAA is associated with lower cognitive performance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15956274     DOI: 10.1176/appi.ajgp.13.6.535

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  17 in total

1.  Prescription patterns of anticholinergic agents and their associated factors in Korean elderly patients with dementia.

Authors:  Eun Kyung Lee; Yu Jeung Lee
Journal:  Int J Clin Pharm       Date:  2013-05-25

2.  Anticholinergic Drug Use and Risk to Cognitive Performance in Older Adults with Questionable Cognitive Impairment: A Cross-Sectional Analysis.

Authors:  Sunil Swami; Ronald A Cohen; John A Kairalla; Todd M Manini
Journal:  Drugs Aging       Date:  2016-11       Impact factor: 3.923

3.  The relationship between anticholinergic medications and Mini-Cog scores in older adults receiving home health care.

Authors:  Susan L Lakey; Peggy S Odegard; Travis E Sonnett; Stephen M Setter; Soo Borson
Journal:  Consult Pharm       Date:  2009-09

4.  Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study.

Authors:  Luca Pasina; Codjo D Djade; Ugo Lucca; Alessandro Nobili; Mauro Tettamanti; Carlotta Franchi; Francesco Salerno; Salvatore Corrao; Alessandra Marengoni; Alfonso Iorio; Maura Marcucci; Francesco Violi; Pier Mannuccio Mannucci
Journal:  Drugs Aging       Date:  2013-02       Impact factor: 3.923

5.  Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.

Authors:  Hitoshi Sakurai; Robert R Bies; Scott T Stroup; Richard S E Keefe; Tarek K Rajji; Takefumi Suzuki; David C Mamo; Bruce G Pollock; Koichiro Watanabe; Masaru Mimura; Hiroyuki Uchida
Journal:  Schizophr Bull       Date:  2012-01-30       Impact factor: 9.306

6.  Evidence and consensus-based German guidelines for the management of analgesia, sedation and delirium in intensive care--short version.

Authors:  Jörg Martin; Anja Heymann; Katrin Bäsell; Ralf Baron; Rolf Biniek; Hartmut Bürkle; Peter Dall; Christine Dictus; Verena Eggers; Ingolf Eichler; Lothar Engelmann; Lars Garten; Wolfgang Hartl; Ulrike Haase; Ralf Huth; Paul Kessler; Stefan Kleinschmidt; Wolfgang Koppert; Franz-Josef Kretz; Heinz Laubenthal; Guenter Marggraf; Andreas Meiser; Edmund Neugebauer; Ulrike Neuhaus; Christian Putensen; Michael Quintel; Alexander Reske; Bernard Roth; Jens Scholz; Stefan Schröder; Dierk Schreiter; Jürgen Schüttler; Gerhard Schwarzmann; Robert Stingele; Peter Tonner; Philip Tränkle; Rolf Detlef Treede; Tomislav Trupkovic; Michael Tryba; Frank Wappler; Christian Waydhas; Claudia Spies
Journal:  Ger Med Sci       Date:  2010-02-02

Review 7.  Over-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults.

Authors:  Daniel M I Britt; Gregory S Day
Journal:  Mo Med       Date:  2016 May-Jun

8.  Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia.

Authors:  Jessica A Wojtalik; Shaun M Eack; Bruce G Pollock; Matcheri S Keshavan
Journal:  Psychiatry Res       Date:  2012-11-15       Impact factor: 3.222

9.  The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia.

Authors:  Sophia Vinogradov; Melissa Fisher; Heather Warm; Christine Holland; Margaret A Kirshner; Bruce G Pollock
Journal:  Am J Psychiatry       Date:  2009-07-01       Impact factor: 18.112

Review 10.  The cognitive impact of anticholinergics: a clinical review.

Authors:  Noll Campbell; Malaz Boustani; Tony Limbil; Carol Ott; Chris Fox; Ian Maidment; Cathy C Schubert; Stephanie Munger; Donna Fick; David Miller; Rajesh Gulati
Journal:  Clin Interv Aging       Date:  2009-06-09       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.